Daxor Corp.

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN.

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.   The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

Data Led to Multi-Center Study In Progress At Three Leading Hospitals

Daxor's Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has signed a non-government distribution agreement with Concordance Healthcare Solutions, one of the largest independent healthcare distributors in the U.S. Daxor and Concordance will work together to provide Daxor's BVA-100® (Blood Volume Analyzer) diagnostic blood test to healthcare facilities nationally, driving the use of blood volume measurement to help guide precise, individualized volume management in a wide variety of medical conditions including heart failure and critical care.

DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE® HEALTHCARE SOLUTIONS

Cites Evidence from Studies Utilizing Daxor's BVA-100® Blood Volume Analyzer

American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer will present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 2, 2021 at 4:30 PM ET.

Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions of Daxor's BVA-100 Blood Volume Analyzer slated for Q3 2021 at major medical centers across the U.S.

Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in postural tachycardia syndrome (POTS) published in the Journal of the American College of Cardiology from the Vanderbilt Autonomic Dysfunction Center in Nashville, TN.

Newly Published Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at Maxim Group 2021 Emerging Growth Virtual Conference to be held March 17-19, 2021, 9:00 AM - 5:00 PM EST.

Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference

BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE

DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER

Revenues of Operating Division Increase by 50.4%

Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020

Important Milestone for International Distribution

DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)

NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center (M2D2) funded by the National Heart, Lung, and Blood Institute and the National Center for Complementary and Integrative Health, both part of the National Institutes of Health (NIH), to develop a smart, point-of-care heart failure diagnostic for quantification of intravascular fluid overload to enable precision diuretic dosing.

DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER

Study Presented At the Society for Critical Care Medicine (SCCM) 50th Congress

New Research Demonstrates the Clinical Utility with Daxor's Blood Volume Analyzer (BVA-100®) in Critical Care

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), announces today that it has signed a new distribution agreement with L1 Enterprises, a leading provider of medical equipment and supplies to the government marketplace including the Department of Defense (DOD), Department of Veterans Affairs (VA), Health and Human Services (HHS) and the National Institute of Standards and Technology (NIST). Daxor and L1 Enterprises will work together to provide Daxor's BVA-100 (Blood Volume Analysis) diagnostic blood test (“BVA''), driving the use of BVA to help guide precise, individualized volume management in a wide variety of medical conditions including heart failure and critical care.

DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH L1 ENTERPRISES GOVERNMENT DISTRIBUTOR

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Daxor's President & Chief Executive Officer, will present at the inaugural H.C. Wainwright BioConnect Investment Conference which is being held from January 11th to 14th through a virtual format with on-demand video presentations.

Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference

NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor's BVA-100® Blood Volume Analyzer at major medical centers across the U.S.

Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

NEW YORK, NY, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer, will present at the virtual 2020 LD MicroCap Main Event on December 14, 2020 at 10:40 AM ET in Track One: Top Dollar.

Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. Wake Forest School of Medicine is based in Winston-Salem, North Carolina, and is set to enroll patients under the leadership of Ashish K. Khanna, MD.

THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY

COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor's Blood Volume Analysis Technology

OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY

NEW YORK, NY, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer, will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on Tuesday, October 13th at 3:00 PM ET.

Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl

NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data presented during the Heart Failure Society of America’s Annual Scientific Meeting focused on the use of Daxor’s BVA-100® blood test for uniquely measuring anemia.

New Research Shows Daxor’s BVA-100® Blood Test Provides Unique Benefit in Detecting Anemia and Heart Failure Risk, Presented at the Heart Failure Society of America Meeting 2020

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces compelling new data demonstrating further beneficial use of Daxor’s blood volume analysis technology presented during the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020.

New Research Demonstrates Daxor BVA-100® Blood Test Provides “Extremely Cost-Effective” Improvement in Patient Life Span at the Heart Failure Society of America Annual Scientific Meeting 2020

NEW YORK, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data from the Mayo Clinic showing that Daxor’s Blood Volume diagnostic test utilizing its BVA-100 device is clinically superior to the common proxy marker of weight loss to measure progress in heart failure (HF) treatment. This data was presented at the Heart Failure Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020 currently in progress.

New Data Released from the Mayo Clinic Utilizing Daxor’s BVA-100® Test Highlights Value of Daxor’s Diagnostic at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020

NEW YORK, Sept.  28, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be exhibiting and showcasing new data at the Heart Failure Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020 taking place from September 30th - October 6th, 2020.

Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 on the Value of BVA-100®

NEW YORK, Sept.  15, 2020  (GLOBE NEWSWIRE) --  Daxor Corporation  (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be participating in the inaugural Sepsis Alliance Summit. Michael Feldschuh, President and Chief Executive Officer of Daxor, will present as part of a Panel Discussion: Connecting Innovation to Clinicians: The Development Story to Improve Sepsis Care on Thursday, September 17th, 2020, at 1:30 PM ET.

Daxor to Present at the Inaugural Sepsis Alliance Summit

NEW YORK, Sept.  10, 2020  (GLOBE NEWSWIRE) --  Daxor Corporation  (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 2:00 PM ET.

News for Daxor Corp. Stock (DXR)